{"filing":{"accession_number":"0001213900-26-093544","cik":"0001513525","ticker":"ADIL","company_name":"ADIAL PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-19","primary_document":"ea0303369-8k_adial.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026093544/ea0303369-8k_adial.htm"},"events":[{"id":29521,"run_id":27033,"accession_number":"0001213900-26-093544","anchor_item_number":"3.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses a material inducement stock option grant of 307,814 shares to an individual becoming an employee, approved by the Compensation Committee and issued under Nasdaq Rule 5635(c)(4). While Item 3.02 typically covers dilutive equity issuances, the substance here is an executive compensation arrangement—a stock option award with vesting conditions tied to continued service. This is a compensatory arrangement for a named executive or officer, making exec_compensation the most precise classification, though the Item 3.02 designation and unregistered securities language create some ambiguity.","company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31832,"accession_number":"0001213900-26-093544","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material inducement stock option grant of 307,814 shares to an individual becoming an employee, approved by the Compensation Committee and issued under Nasdaq Rule 5635(c)(4). While Item 3.02 typically covers dilutive equity issuances, the substance here is an executive compensation arrangement—a stock option award with vesting conditions tied to continued service. This is a compensatory arrangement for a named executive or officer, making exec_compensation the most precise classification, though the Item 3.02 designation and unregistered securities language create some ambiguity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:35:22.120383+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31832,"accession_number":"0001213900-26-093544","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material inducement stock option grant of 307,814 shares to an individual becoming an employee, approved by the Compensation Committee and issued under Nasdaq Rule 5635(c)(4). While Item 3.02 typically covers dilutive equity issuances, the substance here is an executive compensation arrangement—a stock option award with vesting conditions tied to continued service. This is a compensatory arrangement for a named executive or officer, making exec_compensation the most precise classification, though the Item 3.02 designation and unregistered securities language create some ambiguity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:35:22.120383+00:00","company_name":"ADIAL PHARMACEUTICALS, INC.","ticker":"ADIL","filing_date":"2026-08-25"}]}